Stay updated with breaking news from Mediated Excision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late-breaking, oral presentation highlights ability of ARCUS gene editing approach to achieve large gene excisions enabling significant functional muscle improvement in preclinical study ... | May 19, 2023
Late-Breaking Abstract Demonstrates Capabilities of ARCUS for Large Gene Excision In VivoDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that its late-...
Late-Breaking Abstract Demonstrates Capabilities of ARCUS for Large Gene Excision In Vivo ... | May 12, 2023
DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking... | April 19, 2023
- Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy ... | April 18, 2023